ATE520988T1 - Verfahren und zusammensetzungen zur bewertung einer brustkrebsprognose - Google Patents

Verfahren und zusammensetzungen zur bewertung einer brustkrebsprognose

Info

Publication number
ATE520988T1
ATE520988T1 AT05810348T AT05810348T ATE520988T1 AT E520988 T1 ATE520988 T1 AT E520988T1 AT 05810348 T AT05810348 T AT 05810348T AT 05810348 T AT05810348 T AT 05810348T AT E520988 T1 ATE520988 T1 AT E520988T1
Authority
AT
Austria
Prior art keywords
methods
prognosis
evaluation
compositions
computer program
Prior art date
Application number
AT05810348T
Other languages
English (en)
Inventor
Timothy Fischer
Clark Whitehead
Douglas Malinowski
Raphael Marcelpoil
Didier Morel
Original Assignee
Tripath Imaging Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tripath Imaging Inc filed Critical Tripath Imaging Inc
Application granted granted Critical
Publication of ATE520988T1 publication Critical patent/ATE520988T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Theoretical Computer Science (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Medical Informatics (AREA)
  • Evolutionary Biology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Apparatus For Radiation Diagnosis (AREA)
AT05810348T 2004-09-22 2005-09-22 Verfahren und zusammensetzungen zur bewertung einer brustkrebsprognose ATE520988T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US61207304P 2004-09-22 2004-09-22
US61196504P 2004-09-22 2004-09-22
PCT/US2005/034152 WO2006036788A2 (en) 2004-09-22 2005-09-22 Methods and compositions for evaluating breast cancer prognosis

Publications (1)

Publication Number Publication Date
ATE520988T1 true ATE520988T1 (de) 2011-09-15

Family

ID=35695736

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05810348T ATE520988T1 (de) 2004-09-22 2005-09-22 Verfahren und zusammensetzungen zur bewertung einer brustkrebsprognose

Country Status (11)

Country Link
US (3) US7899623B2 (de)
EP (2) EP1800130B1 (de)
JP (2) JP2008513032A (de)
KR (2) KR20070061893A (de)
AT (1) ATE520988T1 (de)
AU (2) AU2005289756B2 (de)
BR (2) BRPI0515562A (de)
CA (2) CA2580795A1 (de)
IL (2) IL182062A0 (de)
MX (1) MX2007003502A (de)
WO (2) WO2006036726A1 (de)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8594410B2 (en) * 2006-08-28 2013-11-26 Definiens Ag Context driven image mining to generate image-based biomarkers
US20060003391A1 (en) * 2003-08-11 2006-01-05 Ring Brian Z Reagents and methods for use in cancer diagnosis, classification and therapy
US20050112622A1 (en) * 2003-08-11 2005-05-26 Ring Brian Z. Reagents and methods for use in cancer diagnosis, classification and therapy
US20080131916A1 (en) * 2004-08-10 2008-06-05 Ring Brian Z Reagents and Methods For Use In Cancer Diagnosis, Classification and Therapy
US8114615B2 (en) 2006-05-17 2012-02-14 Cernostics, Inc. Method for automated tissue analysis
KR100786759B1 (ko) * 2006-07-07 2007-12-18 김현기 Ｈｃｃｒ-1을 포함하는 유방암 예후 마커 및 비만 유도조성물
WO2008008284A2 (en) 2006-07-14 2008-01-17 The Regents Of The University Of California Cancer biomarkers and methods of use threof
CA2663595A1 (en) * 2006-08-07 2008-02-14 The Board Of Regents Of The University Of Texas System Proteomic patterns of cancer prognostic and predictive signatures
WO2008043104A2 (en) * 2006-10-06 2008-04-10 Applied Genomics Inc. Reagents and methods for use in cancer diagnosis, classification and therapy
ES2374686T3 (es) * 2007-05-14 2012-02-21 Historx, Inc. Separación en compartimentos por caracterización de píxel usando agrupamiento de datos de imágenes.
WO2008157277A1 (en) * 2007-06-15 2008-12-24 The University Of North Carolina At Chapel Hill Methods for evaluating breast cancer prognosis
EP2162728B1 (de) 2007-06-15 2016-07-27 Novartis AG Mikroskopisches system und verfahren zur erfassung von standardisierten daten
CA2604317C (en) 2007-08-06 2017-02-28 Historx, Inc. Methods and system for validating sample images for quantitative immunoassays
CA2596204C (en) * 2007-08-07 2019-02-26 Historx, Inc. Method and system for determining an optimal dilution of a reagent
WO2009029810A1 (en) * 2007-08-31 2009-03-05 Historx, Inc. Automatic exposure time selection for imaging tissue
EP2034027A1 (de) * 2007-09-04 2009-03-11 Siemens Healthcare Diagnostics GmbH Molekulare Marker zur Vorhersage der Reaktion auf eine Chemotherapie und Hemmung der EGFR-Familie durch gezielte Strategien
BRPI0815460A2 (pt) * 2007-09-07 2019-02-26 Univ Bruxelles kit de diagnóstico ou dispositivo e método para prognóstico de cancro em sujeitos mamíferos
GB0720113D0 (en) * 2007-10-15 2007-11-28 Cambridge Cancer Diagnostics L Diagnostic, prognostic and predictive testing for cancer
WO2009055480A2 (en) * 2007-10-22 2009-04-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Tgf-beta gene expression signature in cancer prognosis
WO2009089521A2 (en) * 2008-01-10 2009-07-16 Nuvera Biosciences, Inc. Predictors for evaluating response to cancer therapy
MX2010014280A (es) * 2008-06-26 2011-05-23 Dana Farber Cancer Inst Inc Distintivos y determinantes asociados con metástasis y método para utilizarlos.
ES2338843B1 (es) * 2008-07-02 2011-01-24 Centro De Investigaciones Energeticas, Medioambientales Y Tecnologicas Huella genomica de cancer de mama.
CN105362277A (zh) 2008-07-16 2016-03-02 药品循环有限公司 用于实体肿瘤的治疗的布鲁顿酪氨酸激酶的抑制剂
AU2009293380B2 (en) * 2008-09-16 2016-05-19 Novartis Ag Reproducible quantification of biomarker expression
US20100124747A1 (en) * 2008-11-03 2010-05-20 University Of Southern California Compositions and methods for diagnosis or prognosis of testicular cancer
US20100120080A1 (en) * 2008-11-03 2010-05-13 Quest Diagnostics Investments Incorporated Cancer diagnosis using ki-67
KR101141103B1 (ko) * 2009-12-15 2012-05-02 계명대학교 산학협력단 임상진단 결정 규칙 생성 방법
PL2553118T3 (pl) * 2010-03-31 2015-03-31 Sividon Diagnostics Gmbh Sposób przewidywania nawrotu raka sutka podczas leczenia endokrynologicznego
EP3508854A1 (de) * 2010-04-27 2019-07-10 The Regents of The University of California Krebsbiomarker und verfahren zur verwendung davon
CA3007787C (en) 2010-06-03 2020-03-10 Pharmacyclics Llc The use of inhibitors of bruton's tyrosine kinase (btk)
US9129426B2 (en) 2010-08-31 2015-09-08 General Electric Company Motion compensation in image processing
FR2964744B1 (fr) * 2010-09-10 2015-04-03 Univ Versailles St Quentin En Yvelines Test pronostic de l'evolution d'une tumeur solide par analyse d'images
US10018631B2 (en) 2011-03-17 2018-07-10 Cernostics, Inc. Systems and compositions for diagnosing Barrett's esophagus and methods of using the same
BR112014000653A2 (pt) 2011-07-13 2017-02-14 Pharmacyclics Inc inibidores de tirosina quinase de bruton
US20130096021A1 (en) * 2011-09-27 2013-04-18 Arul M. Chinnaiyan Recurrent gene fusions in breast cancer
US9115388B2 (en) 2011-11-01 2015-08-25 H. Lee Moffitt Cancer Center And Research Institute, Inc. Gene signature for the prediction of NF-kappaB activity
US8885912B2 (en) * 2011-11-03 2014-11-11 General Electric Company Generate percentage of positive cells for biomarkers by normalizing and autothresholding the image intensity produced by immunohistochemistry technique
JP6301258B2 (ja) * 2011-11-03 2018-03-28 トライパス イメージング インコーポレイテッド 免疫染色試料を調製するための方法および構成物
EP2839034A4 (de) * 2012-04-20 2016-01-06 Sloan Kettering Inst Cancer Mit metastasierendem brustkrebs assoziierte genexpressionsprofile
US8737709B2 (en) * 2012-04-30 2014-05-27 General Electric Company Systems and methods for performing correlation analysis on clinical outcome and characteristics of biological tissue
EP2845138A1 (de) * 2012-04-30 2015-03-11 General Electric Company Systeme und verfahren zur analyse der biomarker co-lokalisierung in einem biologischen gewebe
CA2879570A1 (en) 2012-07-24 2014-01-30 Pharmacyclics, Inc. Mutations associated with resistance to inhibitors of bruton's tyrosine kinase (btk)
WO2014016401A1 (en) * 2012-07-27 2014-01-30 Centre Leon Berard DETECTION OF THE ERα/SRC/PI3K COMPLEX AS PREDICTIVE MARKER IN BREAST CANCER
JP2014123230A (ja) * 2012-12-20 2014-07-03 Sony Corp 画像処理装置、画像処理方法、及び、プログラム
CN103136333B (zh) * 2013-01-29 2016-08-10 冯力新 一种抽象属性的量化评价分析方法
CN103293321B (zh) * 2013-05-27 2015-05-13 北京大学 一种检测dna损伤诱导的早期核仁应激的试剂盒及其应用
ES2709509T3 (es) 2013-08-12 2019-04-16 Pharmacyclics Llc Procedimientos para el tratamiento de cáncer amplificado por HER2
US9519823B2 (en) * 2013-10-04 2016-12-13 The University Of Manchester Biomarker method
US9953417B2 (en) 2013-10-04 2018-04-24 The University Of Manchester Biomarker method
US9785752B1 (en) * 2014-02-25 2017-10-10 Flagship Biosciences, Inc. Method for stratifying and selecting candidates for receiving a specific therapeutic approach
EP3119910A4 (de) 2014-03-20 2018-02-21 Pharmacyclics LLC Phospholipase c gamma 2 und resistenzassoziierte mutationen
WO2015148825A2 (en) * 2014-03-27 2015-10-01 Rong Li Methods and compositions for evaluating breast cancer patients
WO2015189264A1 (en) 2014-06-10 2015-12-17 Ventana Medical Systems, Inc. Predicting breast cancer recurrence directly from image features computed from digitized immunohistopathology tissue slides
CN113559075A (zh) 2014-11-17 2021-10-29 康泰科思特生物制药公司 奥那司酮延长释放组合物和方法
EP3227687A4 (de) 2014-12-05 2018-10-24 Prelude, Inc. Dcis-wiederauftreten und invasiver brustkrebs
US20180040120A1 (en) * 2014-12-29 2018-02-08 Flagship Biosciences, Inc. Methods for quantitative assessment of mononuclear cells in muscle tissue sections
KR101765999B1 (ko) 2015-01-21 2017-08-08 서울대학교산학협력단 암 바이오마커의 성능 평가 장치 및 방법
US10115187B2 (en) * 2015-01-30 2018-10-30 Raytheon Company Apparatus and processes for classifying and counting corn kernels
CA2998924A1 (en) 2015-09-25 2017-03-30 Context Biopharma Inc. Methods of making onapristone intermediates
EP3380840B1 (de) 2015-11-25 2020-08-19 Cernostics, Inc. Verfahren zur vorhersage der progression von barrett-ösophagus
US20190113423A1 (en) * 2015-12-02 2019-04-18 Clearlight Diagnostics, LLC Methods for preparing and analyzing tumor tissue samples for detection and monitoring of cancers
JP2019503353A (ja) 2015-12-15 2019-02-07 コンテキスト・バイオファーマ・インコーポレイテッド 非晶質オナプリストン組成物およびそれを作製する方法
KR20180115725A (ko) 2016-02-08 2018-10-23 이마고 시스템즈, 인크. 이미지 내의 대상의 시각화와 특징화를 위한 시스템 및 방법
EP3430022B1 (de) 2016-03-14 2020-03-11 Somalogic, Inc. Verbindungen und verfahren zur herstellung von 5-(n-geschützten-tryptaminocarboxyamide)-2'-deoxyuridine phosphoramiditen sowie ihr einbau in einer nukleotidsäuresequenz
WO2017156627A1 (en) * 2016-03-14 2017-09-21 Proteocyte Diagnostics Inc. Automated method for assessing cancer risk using tissue samples, and system therefor
WO2017182985A1 (en) * 2016-04-20 2017-10-26 Morphotek, Inc. Prognosis of serous ovarian cancer using biomarkers
US20180148471A1 (en) 2016-11-30 2018-05-31 Arno Therapeutics, Inc. Methods for onapristone synthesis dehydration and deprotection
CA3108862A1 (en) 2017-08-07 2019-02-14 Imago Systems, Inc. System and method for the visualization and characterization of objects in images
EP3850368A4 (de) 2018-09-14 2022-11-23 Prelude Corporation Verfahren zur auswahl zur behandlung von subjekten mit risiko auf invasiven brustkrebs
US12260607B2 (en) 2018-12-15 2025-03-25 The Brigham And Women's Hospital, Inc. Augmented digital microscopy for lesion analysis
AU2021309571A1 (en) 2020-07-17 2023-03-16 European Molecular Biology Laboratory Prognostic biomarkers for cancer
CN114959026A (zh) * 2022-04-15 2022-08-30 深圳市陆为生物技术有限公司 检测基因的试剂在制备用于评价乳腺癌患者复发风险的产品中的应用
EP4646208A1 (de) 2023-01-06 2025-11-12 Ideaya Biosciences, Inc. Behandlung von er+-brustkrebs mit mangel an homologer rekombination unter verwendung eines parg-hemmers

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ201918A (en) 1981-09-18 1987-04-30 Genentech Inc N-terminal methionyl analogues of bovine growth hormone
US4708871A (en) 1983-03-08 1987-11-24 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
WO1994000591A1 (fr) * 1992-06-26 1994-01-06 Nippon Shinyaku Co., Ltd. Anticorps monoclonal, son procede d'obtention, cellule productrice de cet anticorps, et methode de diagnostic
EP0745243B9 (de) * 1994-02-14 2008-01-02 AutoCyte North Carolina LLC Automatisiertes cytologisches probenklassifizierungsverfahren
US5989811A (en) * 1994-09-29 1999-11-23 Urocor, Inc. Sextant core biopsy predictive mechanism for non-organ confined disease status
US5869040A (en) * 1995-06-07 1999-02-09 Biogen, Inc Gene therapy methods and compositions
WO1998008439A1 (en) * 1996-08-25 1998-03-05 Sensar, Inc. Apparatus for the iris acquiring images
US5798266A (en) * 1996-08-27 1998-08-25 K-Quay Enterprises, Llc Methods and kits for obtaining and assaying mammary fluid samples for breast diseases, including cancer
EP0943095A2 (de) * 1996-11-22 1999-09-22 Shiloov Medical Technologies, Ltd. Testverfahren und kit zur früherkennung von krebspatienten unter verwendung von ganzem blut und mitogene
EP1131470A4 (de) * 1998-10-28 2004-11-10 Vysis Inc Zelluläre arrays sowie verfahren zur detektion und verwendung von markern für genetische störungen
WO2000047998A1 (en) * 1999-02-10 2000-08-17 Cell Works Inc. Class characterization of circulating cancer cells isolated from body fluids and methods of use
EP1159619A2 (de) * 1999-03-15 2001-12-05 EOS Biotechnology, Inc. Verfahren zur diagnose und zum behandeln von brustkrebs
US6642009B2 (en) * 1999-05-17 2003-11-04 Cytyc Health Corporation Isolated ductal fluid sample
US20030087265A1 (en) * 2000-01-21 2003-05-08 Edward Sauter Specific microarrays for breast cancer screening
AU781992B2 (en) * 2000-04-04 2005-06-23 Medical Research Council Methods involving induced dimerisation by cellular components
IL152428A0 (en) * 2000-04-26 2003-05-29 Univ Kingston Formulations and method of using nitric oxide mimetics against a malignant cell phenotype
GB0011439D0 (en) * 2000-05-12 2000-06-28 Novartis Res Found Cancer diagnosis and assays for screening
AU2001278076A1 (en) * 2000-07-26 2002-02-05 Applied Genomics, Inc. Bstp-5 proteins and related reagents and methods of use thereof
US6703204B1 (en) * 2000-07-28 2004-03-09 The Brigham & Women's Hospital, Inc. Prognostic classification of breast cancer through determination of nucleic acid sequence expression
DE10101792B4 (de) * 2001-01-17 2004-03-18 Vivotec Biomedical Technologies Gmbh Verfahren zum Nachweis von Pankreaskarzinom oder chronischer Pankreatitis und Verwendung von Antikörpern
US7171311B2 (en) * 2001-06-18 2007-01-30 Rosetta Inpharmatics Llc Methods of assigning treatment to breast cancer patients
DK1410011T3 (da) * 2001-06-18 2011-07-18 Netherlands Cancer Inst Diagnose og prognose for brystcancerpatienter
JP3721105B2 (ja) * 2001-08-22 2005-11-30 日本電気株式会社 組織検査法を利用する胃癌の切除手術後の予後検査方法
US7065236B2 (en) 2001-09-19 2006-06-20 Tripath Imaging, Inc. Method for quantitative video-microscopy and associated system and computer software program product
US6855554B2 (en) * 2001-09-21 2005-02-15 Board Of Regents, The University Of Texas Systems Methods and compositions for detection of breast cancer
US20040002067A1 (en) * 2001-12-21 2004-01-01 Erlander Mark G. Breast cancer progression signatures
US7133547B2 (en) 2002-01-24 2006-11-07 Tripath Imaging, Inc. Method for quantitative video-microscopy and associated system and computer software program product
AU2003217397A1 (en) * 2002-02-14 2003-09-04 The Johns Hopkins University School Of Medecine Claudins, markers for diagnosis, prognosis and therapy of breast, bone, brain cancer
US20040229299A1 (en) * 2002-05-21 2004-11-18 Badal M. Youssouf Intracellular complexes as biomarkers
US20040018525A1 (en) * 2002-05-21 2004-01-29 Bayer Aktiengesellschaft Methods and compositions for the prediction, diagnosis, prognosis, prevention and treatment of malignant neoplasma
US20040231909A1 (en) * 2003-01-15 2004-11-25 Tai-Yang Luh Motorized vehicle having forward and backward differential structure
WO2004087887A2 (en) * 2003-04-01 2004-10-14 Monogram Biosciences, Inc. Intracellular complexes as biomarkers
CA2545641A1 (en) * 2003-11-17 2005-06-02 Novartis Ag Use of organic compounds
US20050221398A1 (en) * 2004-01-16 2005-10-06 Ipsogen, Sas, A Corporation Of France Protein expression profiling and breast cancer prognosis
WO2005071419A2 (en) * 2004-01-16 2005-08-04 Ipsogen Protein expression profiling and breast cancer prognosis
CN1957256B (zh) * 2004-03-24 2013-01-02 三路影像公司 用于子宫颈疾病检测的方法和组合物

Also Published As

Publication number Publication date
WO2006036788A3 (en) 2006-08-17
AU2005289728B2 (en) 2011-11-24
JP2008513793A (ja) 2008-05-01
KR20070061893A (ko) 2007-06-14
CA2580937A1 (en) 2006-04-06
JP5184087B2 (ja) 2013-04-17
AU2005289756A1 (en) 2006-04-06
KR20070068401A (ko) 2007-06-29
WO2006036726A1 (en) 2006-04-06
AU2005289728A1 (en) 2006-04-06
EP1800130B1 (de) 2011-08-17
US7899623B2 (en) 2011-03-01
BRPI0515562A (pt) 2008-07-29
AU2005289756B2 (en) 2011-10-13
CA2580937C (en) 2016-02-02
WO2006036788A2 (en) 2006-04-06
IL182063A0 (en) 2008-04-13
EP1800130A2 (de) 2007-06-27
US20090269856A1 (en) 2009-10-29
JP2008513032A (ja) 2008-05-01
CA2580795A1 (en) 2006-04-06
US20060063190A1 (en) 2006-03-23
IL182062A0 (en) 2007-07-24
EP1805676A1 (de) 2007-07-11
BRPI0515581A (pt) 2008-07-29
US20060078926A1 (en) 2006-04-13
MX2007003502A (es) 2007-10-10

Similar Documents

Publication Publication Date Title
ATE520988T1 (de) Verfahren und zusammensetzungen zur bewertung einer brustkrebsprognose
Patschan et al. A molecular pathologic framework for risk stratification of stage T1 urothelial carcinoma
Harter et al. Classification of meningiomas—advances and controversies
Hayes Biomarker validation and testing
Klein et al. Prediction of the Oncotype DX recurrence score: use of pathology-generated equations derived by linear regression analysis
Schweizer et al. Metastasis-free survival is associated with overall survival in men with PSA-recurrent prostate cancer treated with deferred androgen deprivation therapy
van der Schroeff et al. Staging and prognosis in head and neck cancer
Liang et al. Application of single-cell technology in cancer research
Bhargava et al. The healthcare value of the Magee Decision Algorithm™: use of Magee Equations™ and mitosis score to safely forgo molecular testing in breast cancer
Van den Broeck et al. Validation of the decipher test for predicting distant metastatic recurrence in men with high-risk nonmetastatic prostate cancer 10 years after surgery
Bischoff et al. Is above age 45 appropriate for upstaging well-differentiated papillary thyroid cancer?
DE602005019294D1 (de) Mrna-verhältnisse in harnsedimenten und/oder harn als prognostische und/oder theranostische marker für prostatakrebs
Bueno et al. Validation of a molecular and pathological model for five-year mortality risk in patients with early stage lung adenocarcinoma
Ambinder et al. Using primary site as a predictor of survival in mantle cell lymphoma
Huang et al. Log odds of positive lymph nodes is a superior prognostic indicator in stage III rectal cancer patients: a retrospective analysis of 17,632 patients in the SEER database
Peng et al. An expression signature at diagnosis to estimate prostate cancer patients’ overall survival
Mahar et al. Refining prognosis in lung cancer: a report on the quality and relevance of clinical prognostic tools
Saldanha et al. 5-Hydroxymethylcytosine is an independent predictor of survival in malignant melanoma
HK1226106A1 (zh) 针对膀胱癌的dna甲基化生物标志物
NO20072296L (no) Fremgangsmater og systemer for prognose og behandling av faste tumorer
Deng et al. Size-adjusted quantitative Gleason score as a predictor of biochemical recurrence after radical prostatectomy
Vuity et al. Is the 8th edition of the Union for International Cancer Control staging of oral cancer good enough?
Strand et al. Long-term prognostic implications of risk factors associated with tumor size: a case study of women regularly attending screening
Andersen et al. Spatial transcriptomics reveals strong association between SFRP4 and extracellular matrix remodeling in prostate cancer
Boissin et al. Deep learning-based risk stratification of preoperative breast biopsies using digital whole slide images

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties